Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 218

1.

Matriptase/epithin participates in mammary epithelial cell growth and morphogenesis through HGF activation.

Lee SL, Huang PY, Roller P, Cho EG, Park D, Dickson RB.

Mech Dev. 2010 Jan-Feb;127(1-2):82-95. doi: 10.1016/j.mod.2009.10.004. Epub 2009 Oct 22.

2.

Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study.

Darcy KM, Brady WE, Blancato JK, Dickson RB, Hoskins WJ, McGuire WP, Birrer MJ.

Gynecol Oncol. 2009 Sep;114(3):472-9. doi: 10.1016/j.ygyno.2009.05.012. Epub 2009 Jun 12.

3.

Calmodulin modulates Akt activity in human breast cancer cell lines.

Coticchia CM, Revankar CM, Deb TB, Dickson RB, Johnson MD.

Breast Cancer Res Treat. 2009 Jun;115(3):545-60. doi: 10.1007/s10549-008-0097-z. Epub 2008 Jun 28.

4.

Pregnancy-upregulated nonubiquitous calmodulin kinase induces ligand-independent EGFR degradation.

Deb TB, Coticchia CM, Barndt R, Zuo H, Dickson RB, Johnson MD.

Am J Physiol Cell Physiol. 2008 Aug;295(2):C365-77. doi: 10.1152/ajpcell.00449.2007. Epub 2008 Jun 18.

5.

Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis.

Calvo A, Catena R, Noble MS, Carbott D, Gil-Bazo I, Gonzalez-Moreno O, Huh JI, Sharp R, Qiu TH, Anver MR, Merlino G, Dickson RB, Johnson MD, Green JE.

Oncogene. 2008 Sep 11;27(40):5373-84. doi: 10.1038/onc.2008.155. Epub 2008 May 26.

6.

EGF receptor in breast cancer chemoresistance.

Dickson RB, Deb TB.

Adv Exp Med Biol. 2007;608:113-8. Review. No abstract available.

PMID:
17993236
7.

Design and synthesis of novel and potent inhibitors of the type II transmembrane serine protease, matriptase, based upon the sunflower trypsin inhibitor-1.

Li P, Jiang S, Lee SL, Lin CY, Johnson MD, Dickson RB, Michejda CJ, Roller PP.

J Med Chem. 2007 Nov 29;50(24):5976-83. Epub 2007 Nov 7.

PMID:
17985858
8.

Zymogen activation, inhibition, and ectodomain shedding of matriptase.

Lin CY, Tseng IC, Chou FP, Su SF, Chen YW, Johnson MD, Dickson RB.

Front Biosci. 2008 Jan 1;13:621-35. Review.

PMID:
17981575
9.

Autoactivation of matriptase in vitro: requirement for biomembrane and LDL receptor domain.

Lee MS, Tseng IC, Wang Y, Kiyomiya K, Johnson MD, Dickson RB, Lin CY.

Am J Physiol Cell Physiol. 2007 Jul;293(1):C95-105. Epub 2007 Mar 7.

10.

Design and synthesis of redox stable analogues of sunflower trypsin inhibitors (SFTI-1) on solid support, potent inhibitors of matriptase.

Jiang S, Li P, Lee SL, Lin CY, Long YQ, Johnson MD, Dickson RB, Roller PP.

Org Lett. 2007 Jan 4;9(1):9-12.

PMID:
17192072
11.

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW.

Cancer Cell. 2006 Dec;10(6):515-27.

12.

Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis.

Jin X, Yagi M, Akiyama N, Hirosaki T, Higashi S, Lin CY, Dickson RB, Kitamura H, Miyazaki K.

Cancer Sci. 2006 Dec;97(12):1327-34. Epub 2006 Sep 25.

13.

A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.

Saleem M, Adhami VM, Zhong W, Longley BJ, Lin CY, Dickson RB, Reagan-Shaw S, Jarrard DF, Mukhtar H.

Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):217-27.

14.

Fluorescence in situ hybridization assessment of c-myc gene amplification in breast tumor tissues.

Blancato JK, Williams MS, Dickson RB.

Methods Mol Med. 2006;120:297-307.

PMID:
16491608
15.

Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells.

Kiyomiya K, Lee MS, Tseng IC, Zuo H, Barndt RJ, Johnson MD, Dickson RB, Lin CY.

Am J Physiol Cell Physiol. 2006 Jul;291(1):C40-9. Epub 2006 Feb 8.

16.

Co-expression of matriptase and N-acetylglucosaminyltransferase V in thyroid cancer tissues--its possible role in prolonged stability in vivo by aberrant glycosylation.

Ito Y, Akinaga A, Yamanaka K, Nakagawa T, Kondo A, Dickson RB, Lin CY, Miyauchi A, Taniguchi N, Miyoshi E.

Glycobiology. 2006 May;16(5):368-74. Epub 2006 Feb 6.

PMID:
16464868
17.
18.

Coexpression of beta1,6-N-acetylglucosaminyltransferase V glycoprotein substrates defines aggressive breast cancers with poor outcome.

Siddiqui SF, Pawelek J, Handerson T, Lin CY, Dickson RB, Rimm DL, Camp RL.

Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2517-23.

19.

Indole-3-carbinol activates the ATM signaling pathway independent of DNA damage to stabilize p53 and induce G1 arrest of human mammary epithelial cells.

Brew CT, Aronchik I, Hsu JC, Sheen JH, Dickson RB, Bjeldanes LF, Firestone GL.

Int J Cancer. 2006 Feb 15;118(4):857-68.

20.

Differential alteration of stem and other cell populations in ducts and lobules of TGFalpha and c-Myc transgenic mouse mammary epithelium.

Chepko G, Slack R, Carbott D, Khan S, Steadman L, Dickson RB.

Tissue Cell. 2005 Oct;37(5):393-412.

PMID:
16137731
21.

Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia.

Lee JW, Yong Song S, Choi JJ, Lee SJ, Kim BG, Park CS, Lee JH, Lin CY, Dickson RB, Bae DS.

Hum Pathol. 2005 Jun;36(6):626-33.

PMID:
16021568
22.

Production of soluble matriptase by human cancer cell lines and cell surface activation of its zymogen by trypsin.

Jin X, Hirosaki T, Lin CY, Dickson RB, Higashi S, Kitamura H, Miyazaki K.

J Cell Biochem. 2005 Jun 1;95(3):632-47.

PMID:
15832373
23.

Pentameric procyanidin from Theobroma cacao selectively inhibits growth of human breast cancer cells.

Ramljak D, Romanczyk LJ, Metheny-Barlow LJ, Thompson N, Knezevic V, Galperin M, Ramesh A, Dickson RB.

Mol Cancer Ther. 2005 Apr;4(4):537-46.

24.

HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease.

Oberst MD, Chen LY, Kiyomiya K, Williams CA, Lee MS, Johnson MD, Dickson RB, Lin CY.

Am J Physiol Cell Physiol. 2005 Aug;289(2):C462-70. Epub 2005 Mar 30.

25.

Simultaneous activation and hepatocyte growth factor activator inhibitor 1-mediated inhibition of matriptase induced at activation foci in human mammary epithelial cells.

Lee MS, Kiyomiya K, Benaud C, Dickson RB, Lin CY.

Am J Physiol Cell Physiol. 2005 Apr;288(4):C932-41. Epub 2004 Dec 8.

26.

Bax regulates c-Myc-induced mammary tumour apoptosis but not proliferation in MMTV-c-myc transgenic mice.

Jamerson MH, Johnson MD, Korsmeyer SJ, Furth PA, Dickson RB.

Br J Cancer. 2004 Oct 4;91(7):1372-9.

27.

Calmodulin-mediated activation of Akt regulates survival of c-Myc-overexpressing mouse mammary carcinoma cells.

Deb TB, Coticchia CM, Dickson RB.

J Biol Chem. 2004 Sep 10;279(37):38903-11. Epub 2004 Jul 9.

28.

Explant-cell culture of primary mammary tumors from MMTV-c-Myc transgenic mice.

Pei XF, Noble MS, Davoli MA, Rosfjord E, Tilli MT, Furth PA, Russell R, Johnson MD, Dickson RB.

In Vitro Cell Dev Biol Anim. 2004 Jan-Feb;40(1-2):14-21.

PMID:
15180438
29.

Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer.

Cavalli LR, Singh B, Isaacs C, Dickson RB, Haddad BR.

Cancer Genet Cytogenet. 2004 Feb;149(1):38-43.

PMID:
15104281
31.

Of mice and Myc: c-Myc and mammary tumorigenesis.

Jamerson MH, Johnson MD, Dickson RB.

J Mammary Gland Biol Neoplasia. 2004 Jan;9(1):27-37. Review.

PMID:
15082916
32.

Assembly of adherens junctions is required for sphingosine 1-phosphate-induced matriptase accumulation and activation at mammary epithelial cell-cell contacts.

Hung RJ, Hsu IaW, Dreiling JL, Lee MJ, Williams CA, Oberst MD, Dickson RB, Lin CY.

Am J Physiol Cell Physiol. 2004 May;286(5):C1159-69.

33.

Detection of LOH and mitochondrial DNA alterations in ductal lavage and nipple aspirate fluids from hngh-risk patients.

Isaacs C, Cavalli LR, Cohen Y, Pennanen M, Shankar LK, Freedman M, Singh B, Liu M, Gallagher A, Rone JD, Dickson RB, Sidransky D, Haddad BR.

Breast Cancer Res Treat. 2004 Mar;84(2):99-105.

PMID:
14999140
34.

Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase.

Suzuki M, Kobayashi H, Kanayama N, Saga Y, Suzuki M, Lin CY, Dickson RB, Terao T.

J Biol Chem. 2004 Apr 9;279(15):14899-908. Epub 2004 Jan 27.

35.

Early parity significantly elevates mammary tumor incidence in MMTV-c-myc transgenic mice.

Jamerson MH, Johnson MD, Furth PA, Dickson RB.

Transgenic Res. 2003 Dec;12(6):747-50.

PMID:
14713205
36.

Cell death in MMTV-c-myc transgenic mouse mammary tumors may not be typical apoptosis.

Liao DJ, Dickson RB.

Lab Invest. 2003 Oct;83(10):1437-49.

PMID:
14563945
37.

c-Myc alters the DNA damage-induced G2/M arrest in human mammary epithelial cells.

Sheen JH, Woo JK, Dickson RB.

Br J Cancer. 2003 Oct 20;89(8):1479-85.

38.

Addition of beta1-6 GlcNAc branching to the oligosaccharide attached to Asn 772 in the serine protease domain of matriptase plays a pivotal role in its stability and resistance against trypsin.

Ihara S, Miyoshi E, Nakahara S, Sakiyama H, Ihara H, Akinaga A, Honke K, Dickson RB, Lin CY, Taniguchi N.

Glycobiology. 2004 Feb;14(2):139-46. Epub 2003 Oct 9.

PMID:
14551220
39.

Type II transmembrane serine proteases.

Szabo R, Wu Q, Dickson RB, Netzel-Arnett S, Antalis TM, Bugge TH.

Thromb Haemost. 2003 Aug;90(2):185-93. Review.

PMID:
12888865
40.

Characterization of matriptase expression in normal human tissues.

Oberst MD, Singh B, Ozdemirli M, Dickson RB, Johnson MD, Lin CY.

J Histochem Cytochem. 2003 Aug;51(8):1017-25.

PMID:
12871983
41.

Epidermal growth factor inhibition of c-Myc-mediated apoptosis through Akt and Erk involves Bcl-xL upregulation in mammary epithelial cells.

Ramljak D, Coticchia CM, Nishanian TG, Saji M, Ringel MD, Conzen SD, Dickson RB.

Exp Cell Res. 2003 Jul 15;287(2):397-410.

PMID:
12837294
42.

Possible role of matriptase in the diagnosis of ovarian cancer.

Johnson MD, Oberst MD, Lin CY, Dickson RB.

Expert Rev Mol Diagn. 2003 May;3(3):331-8. Review.

PMID:
12779007
43.

Ultrastructure of the putative stem cell niche in rat mammary epithelium.

Chepko G, Dickson RB.

Tissue Cell. 2003 Apr;35(2):83-93.

PMID:
12747930
44.

The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor.

Oberst MD, Williams CA, Dickson RB, Johnson MD, Lin CY.

J Biol Chem. 2003 Jul 18;278(29):26773-9. Epub 2003 May 8.

46.

Deregulated activation of matriptase in breast cancer cells.

Benaud CM, Oberst M, Dickson RB, Lin CY.

Clin Exp Metastasis. 2002;19(7):639-49.

PMID:
12498394
48.

Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.

Oberst MD, Johnson MD, Dickson RB, Lin CY, Singh B, Stewart M, Williams A, al-Nafussi A, Smyth JF, Gabra H, Sellar GC.

Clin Cancer Res. 2002 Apr;8(4):1101-7.

49.

Roles of androgens in the development, growth, and carcinogenesis of the mammary gland.

Liao DJ, Dickson RB.

J Steroid Biochem Mol Biol. 2002 Feb;80(2):175-89. Review.

PMID:
11897502
50.

Steroid hormone-growth factor interactions in proliferative controls of the mammary gland and breast cancer: a rapidly evolving perspective.

Liao DJ, Dickson RB.

J Steroid Biochem Mol Biol. 2002 Feb;80(2):135-6. No abstract available.

PMID:
11897498

Supplemental Content

Loading ...
Support Center